Avenue Therapeutics, Inc. Annual report [Section 13 and 15(d), not S-K Item 405]

Annual report [Section 13 and 15(d), not S-K Item 405]

Note 9 - Income Taxes (Tables)

Note 9 - Income Taxes (Tables)

12 Months Ended

Dec. 31, 2025

Notes Tables

Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]

		*For the year ended December 31,*
		*2025*
		*Amount*				*Percent*
U.S. federal statutory tax rate		$	(615	)			21	%
State and local income taxes, net of federal income tax effect(1)			2				0	%
Tax credits			(59	)			2	%
Change in valuation allowance			(870	)			30	%
Non-deductible items			22				-1	%
Other adjustments
Sale of subsidiary(2)			1,522				-52	%
Provision for income taxes and effective income tax rate		$	2				0	%

		*For the year ended December 31,*
		*2024*
Statutory federal income tax rate			21	%
State rate change			(14	)%
Credits			1	%
None-deductible items			1	%
Return to provision			(12	)%
Change in fair value of warrant liability			(2	)%
Change in valuation allowance			6	%
Income taxes provision (benefit)			(0	)%

Schedule of Deferred Tax Assets and Liabilities [Table Text Block]

		*As of December 31,*
		*2025*				*2024*
Deferred tax assets:
Net operating loss carryforwards		$	27,530			$	27,114
Stock compensation and other			520				404
In process research and development			1,303				1,929
Accruals and reserves			38				3
Section 174 capitalization			2,143				2,536
Tax credits			3,043				2,995
Other			23				—
Total deferred tax assets			34,600				34,981
Less: valuation allowance			(34,600	)			(34,981	)
Deferred tax assets, net		$	—			$	—